High comorbidity and tumor proliferation predict survival of localized breast cancer patients after curative surgery: A retrospective analysis of real-world data in Finland

dc.contributor.authorHollmén, Milla
dc.contributor.authorLöyttyniemi, Eliisa
dc.contributor.authorJuhanoja, Eeva
dc.contributor.authorVihinen, Pia
dc.contributor.authorSundvall, Maria
dc.contributor.organizationfi=biolääketieteen laitos|en=Institute of Biomedicine|
dc.contributor.organizationfi=biostatistiikka|en=Biostatistics|
dc.contributor.organizationfi=kliininen laitos|en=Department of Clinical Medicine|
dc.contributor.organizationfi=sisätautioppi|en=Internal Medicine|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organization-code1.2.246.10.2458963.20.61334543354
dc.contributor.organization-code1.2.246.10.2458963.20.77952289591
dc.contributor.organization-code1.2.246.10.2458963.20.89365200099
dc.contributor.organization-code2607100
dc.contributor.organization-code2607318
dc.converis.publication-id484832602
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/484832602
dc.date.accessioned2025-08-28T03:17:06Z
dc.date.available2025-08-28T03:17:06Z
dc.description.abstract<h3>Background</h3><p>The aim of this study was to analyze the characteristics of breast cancer patients and their impact on real-world treatment and survival outcomes.</p><h3>Patients and methods</h3><p>We conducted a retrospective study including all patients newly diagnosed with breast cancer during 2019 in the Southwest Finland. We identified 458 patients diagnosed with either localized (n = 435, 95 %) or metastatic (n = 23, 5 %) breast cancer.</p><h3>Results</h3><p>In localized breast cancer, the five-year overall survival (OS) was 90.9 %, while the five-year disease-free survival (DFS) was 93.5 %. In metastatic breast cancer, the five-year progression-free survival (PFS) was 13.0 % and five-year OS 34.2 %. The median PFS was 10.9 months (95 % CI 2.5–19.4 months) and median OS was 30.6 months (lower 95 % CI 6.9 months – not reached).</p><p>In the univariate analyses, the most important tumor-specific parameters predicting decreased DFS were tumor proliferation index >20 %, low estrogen receptor expression status and tumor size >2 cm. Univariate predictors for decreased OS included Eastern Cooperative Oncology Group (ECOG) performance status ≥2 and Charlson Comorbidity Index (CCI) score ≥3. In the multivariable analyses, CCI score ≥3 and high proliferation index (21–100 % vs. 0–20 %) predicted poorer DFS, while CCI score ≥3 and increased stage (stage 2 vs. 1) predicted poorer OS. The administration of post-operative radiotherapy was significant in the multivariable analyses of both DFS (HR 4.23, 95 % CI 1.85–9.67, p = 0.0006) and OS (HR 6.84, 95 % CI 3.33–14.02, p < 0.0001).</p><h3>Conclusion</h3><p>Our results demonstrate that careful clinical evaluation of ECOG and comorbidities, alongside well-established tumor characteristics predict patient survival in a population where overall five-year survival in breast cancer is over 90 %.<br></p>
dc.identifier.eissn1879-3320
dc.identifier.jour-issn0960-7404
dc.identifier.olddbid210470
dc.identifier.oldhandle10024/193497
dc.identifier.urihttps://www.utupub.fi/handle/11111/51543
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0960740425000039
dc.identifier.urnURN:NBN:fi-fe2025082792711
dc.language.isoen
dc.okm.affiliatedauthorHollmen, Milla
dc.okm.affiliatedauthorLöyttyniemi, Eliisa
dc.okm.affiliatedauthorJuhanoja, Eeva
dc.okm.affiliatedauthorVihinen, Pia
dc.okm.affiliatedauthorSundvall, Maria
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3122 Cancersen_GB
dc.okm.discipline3126 Surgery, anesthesiology, intensive care, radiologyen_GB
dc.okm.discipline3122 Syöpätauditfi_FI
dc.okm.discipline3126 Kirurgia, anestesiologia, tehohoito, radiologiafi_FI
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherElsevier BV
dc.publisher.countryUnited Kingdomen_GB
dc.publisher.countryBritanniafi_FI
dc.publisher.country-codeGB
dc.relation.articlenumber102188
dc.relation.doi10.1016/j.suronc.2025.102188
dc.relation.ispartofjournalSurgical Oncology
dc.relation.volume58
dc.source.identifierhttps://www.utupub.fi/handle/10024/193497
dc.titleHigh comorbidity and tumor proliferation predict survival of localized breast cancer patients after curative surgery: A retrospective analysis of real-world data in Finland
dc.year.issued2025

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
1-s2.0-S0960740425000039-main.pdf
Size:
769.64 KB
Format:
Adobe Portable Document Format